Vasopressin is Used for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. It was first introduced by Endo Operations Ltd in its drug Vasostrict on Apr 17, 2014. Other drugs containing Vasopressin are Vasopressin In Sodium Chloride 0.9%, Vasopressin. 11 different companies have introduced drugs containing Vasopressin.

Vasopressin Patents

Given below is the list of patents protecting Vasopressin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Vasostrict	US10010575	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9375478	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9687526	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9744209	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9744239	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9750785	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9919026	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9925233	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9925234	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9937223	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9962422	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9968649	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9974827	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations
Vasostrict	US9981006	Vasopressin formulations for use in treatment of hypotension	Jan 30, 2035	Endo Operations

Add above patents to watchlist

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vasopressin's patents.

Latest Legal Activities on Vasopressin's Patents

Given below is the list recent legal activities going on the following patents of Vasopressin.

Event	Date	Patent/Publication
Today's Legal Activities
Payment of Maintenance Fee, 8th Year, Large Entity	10 Nov, 2023	US9375478
Email Notification	28 May, 2022	US9925234
Change in Power of Attorney (May Include Associate POA)	27 May, 2022	US9925234
Correspondence Address Change	26 May, 2022	US9925234
Payment of Maintenance Fee, 4th Year, Large Entity	09 Dec, 2021	US10010575
Payment of Maintenance Fee, 4th Year, Large Entity	14 Oct, 2021	US9968649
Payment of Maintenance Fee, 4th Year, Large Entity	14 Oct, 2021	US9974827
Payment of Maintenance Fee, 4th Year, Large Entity	14 Oct, 2021	US9981006
Payment of Maintenance Fee, 4th Year, Large Entity	14 Oct, 2021	US9962422
Payment of Maintenance Fee, 4th Year, Large Entity	09 Sep, 2021	US9937223

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳